Please login to the form below

Not currently logged in


This page shows the latest Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

year. The Swiss pharma company already has an ongoing patent lawsuit against a number of generic drugmakers, including Novartis’ Sandoz division and Teva Pharmaceuticals, which are seeking to bring cheaper, generic

Latest news

More from news
Approximately 105 fully matching, plus 3,054 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 3 fully matching, plus 719 partially matching documents found.

Latest appointments

More from appointments
Approximately 55 fully matching, plus 724 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 54 fully matching, plus 1,034 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...